TY - JOUR
T1 - Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis
AU - Fujita, Kohei
AU - Ohkubo, Hirotsugu
AU - Nakano, Akiko
AU - Mori, Yuta
AU - Fukumitsu, Kensuke
AU - Fukuda, Satoshi
AU - Kanemitsu, Yoshihiro
AU - Uemura, Takehiro
AU - Tajiri, Tomoko
AU - Maeno, Ken
AU - Ito, Yutaka
AU - Oguri, Tetsuya
AU - Ozawa, Yoshiyuki
AU - Murase, Takayuki
AU - Niimi, Akio
N1 - Publisher Copyright:
© The Author(s) 2022.
PY - 2022/7
Y1 - 2022/7
N2 - Objectives: Sarcopenia is a syndrome characterized by reduced muscle mass and function. It is well-recognized as a complication in chronic diseases such as chronic obstructive pulmonary disease. However, little is known about sarcopenia in patients with idiopathic pulmonary fibrosis (IPF). This study aimed to investigate the clinical characteristics of sarcopenia and the association between quality of life and sarcopenia in patients with IPF. Methods: In this pilot cross-sectional study, 56 Japanese outpatients with IPF (49 men) were enrolled prospectively. Sarcopenia was diagnosed according to the criteria of the Asian Working Group for Sarcopenia 2019. Its associations with clinical parameters including age, pulmonary functions, physical performance, and patient-reported outcomes (PROs) were examined. Results: The frequency of sarcopenia was 39.3% (n = 22) in this cohort. There were significant differences in St George’s Respiratory Questionnaire (p =.005), modified Medical Research Council score (p =.004), and Hospital and Anxiety Depression Scale depression score (p =.030) between the sarcopenic and non-sarcopenic groups. On multivariate regression analysis, 6-min walk distance (6MWD) was an independent factor associated with sarcopenia (odds ratio 1.241, 95% confidence interval 1.016–1.515, p =.034). Conclusion: Sarcopenia was associated with PROs and physical performance in patients with IPF.
AB - Objectives: Sarcopenia is a syndrome characterized by reduced muscle mass and function. It is well-recognized as a complication in chronic diseases such as chronic obstructive pulmonary disease. However, little is known about sarcopenia in patients with idiopathic pulmonary fibrosis (IPF). This study aimed to investigate the clinical characteristics of sarcopenia and the association between quality of life and sarcopenia in patients with IPF. Methods: In this pilot cross-sectional study, 56 Japanese outpatients with IPF (49 men) were enrolled prospectively. Sarcopenia was diagnosed according to the criteria of the Asian Working Group for Sarcopenia 2019. Its associations with clinical parameters including age, pulmonary functions, physical performance, and patient-reported outcomes (PROs) were examined. Results: The frequency of sarcopenia was 39.3% (n = 22) in this cohort. There were significant differences in St George’s Respiratory Questionnaire (p =.005), modified Medical Research Council score (p =.004), and Hospital and Anxiety Depression Scale depression score (p =.030) between the sarcopenic and non-sarcopenic groups. On multivariate regression analysis, 6-min walk distance (6MWD) was an independent factor associated with sarcopenia (odds ratio 1.241, 95% confidence interval 1.016–1.515, p =.034). Conclusion: Sarcopenia was associated with PROs and physical performance in patients with IPF.
UR - http://www.scopus.com/inward/record.url?scp=85135599403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135599403&partnerID=8YFLogxK
U2 - 10.1177/14799731221117298
DO - 10.1177/14799731221117298
M3 - Article
C2 - 35930440
AN - SCOPUS:85135599403
SN - 1479-9723
VL - 19
JO - Chronic Respiratory Disease
JF - Chronic Respiratory Disease
ER -